Welcome to our dedicated page for Bayer Aktien news (Ticker: BAYRY), a resource for investors and traders seeking the latest updates and insights on Bayer Aktien stock.
BAYER AG S/ADR (BAYRY) news covers developments at Bayer AG, a global life science enterprise active in health care and nutrition. Company communications highlight updates across its Pharmaceuticals Division, radiology business and crop science activities, giving investors and observers insight into how Bayer advances its pipeline and product portfolio.
Recent pharmaceutical news emphasizes growth in oncology, cardiology, neurology, immunology and women’s health. Examples include updates on asundexian for secondary stroke prevention, finerenone (Kerendia) in cardiovascular-kidney-metabolic conditions, and oncology assets such as Nubeqa for prostate cancer, Hyrnuo for HER2-mutant non-small cell lung cancer, and Xofigo for metastatic castration-resistant prostate cancer with bone metastases. Bayer also reports on Lynkuet, a hormone-free treatment for moderate to severe hot flashes due to menopause, and a Phase III SUNFLOWER study evaluating Mirena for nonatypical endometrial hyperplasia.
News items also describe Bayer’s work in radiology and molecular imaging, including the low-dose MRI contrast agent gadoquatrane and the acquisition of investigational tracers AT-01 and AT-05 for diagnosing cardiac amyloidosis. Additional coverage highlights cell and gene therapy programs for Parkinson’s disease and ophthalmic conditions, as well as collaborations such as the agreement with Soufflé Therapeutics to develop a heart-targeted siRNA therapy for a form of dilated cardiomyopathy.
On the agriculture side, Bayer Crop Science Canada announcements feature launches like Sivanto Energy for flea beetle control in canola and EverGol Rise for pulse disease control. Together, these updates illustrate how Bayer seeks to execute its mission “Health for all, Hunger for none” through pharmaceutical innovation, diagnostic imaging advances and crop protection solutions.
Bayer (OTC:BAYRY) received U.S. FDA Priority Review for its investigational oral Factor XIa inhibitor asundexian to prevent secondary stroke after non-cardioembolic ischemic stroke or TIA.
The NDA is supported by positive Phase III OCEANIC-STROKE results, which met primary efficacy and ISTH major bleeding safety outcomes; asundexian also has FDA Fast Track status.
Bayer (OTC:BAYRY) announced that the U.S. FDA has granted Priority Review to a supplemental new drug application for HYRNUO (sevabertinib) as first-line treatment for adults with locally advanced or metastatic HER2-mutated NSCLC who have not received prior therapy, based on preliminary Phase I/II SOHO-01 data.
Bayer (OTC:BAYRY) reported Phase II ARASEC data showing NUBEQA (darolutamide) plus ADT improved outcomes in U.S. patients with metastatic castration-sensitive prostate cancer (mCSPC) versus a matched ADT-alone historical control from CHAARTED.
The regimen reduced risk of progression or death by 71% and showed significant overall survival and rPFS benefits, with no new safety signals but notable design limitations.
Bayer (OTC:BAYRY) launched the Midol in Motion campaign to help menstruators manage 7 common PMS symptoms through symptom relief and supportive movement. The program combines Midol Complete’s multi-symptom relief with guided exercise routines.
The campaign features live workout events, fitness influencer partnerships, and ongoing digital content across Midol’s social channels.
Bayer (OTC:BAYRY) and country artist Luke Bryan launched a 2026 campaign to expand access to food and nutrition in rural America. Bayer will donate 1 million meals through Feeding America, with food drives and Farm Tour events in Clovis and Elk Grove, California, from May 14–16, 2026.
The partnership, active since 2015, has supported more than 11 million meals for Feeding America member food banks and includes community events, canned food collections, and a limited One A Day x Luke Bryan multivitamin available exclusively at Walmart.
Bayer (OTC: BAYRY) reported that the Phase III REVEAL study met its primary endpoints for iodine 124 evuzamitide PET/CT, demonstrating sensitivity and specificity for diagnosing cardiac amyloidosis by visual scan interpretation.
The tracer retains Breakthrough Therapy and Orphan Drug designations; Bayer plans regulatory discussions with the FDA and other authorities and will present full data at a scientific congress.
Bayer (OTC:BAYRY) will acquire Perfuse Therapeutics, gaining full rights to PER-001, a Phase II endothelin receptor antagonist for Glaucoma and Diabetic Retinopathy.
The deal carries up to USD 2.45 billion in total value, including a USD 300 million upfront payment; closing requires antitrust clearances and Perfuse stockholder approval.
Bayer (OTC: BAYRY) will present 13 abstracts at ESOC 2026 (May 6–8, Maastricht), including two late-breaking analyses from the Phase III OCEANIC-STROKE trial of asundexian.
Late breakers cover incident ischemic stroke characteristics and a net clinical benefit/time-course analysis; four OCEANIC-STROKE sub-analyses and nine real-world stroke outcomes studies will also be presented.
Leaps by Bayer (BAYRY), with BCG and Ipsos UK, published a qualitative April 29, 2026 report decoding public attitudes toward breakthrough science across China, Germany, and the US. Key findings: 64% of global respondents feel positive about AI's impact on human health, Gen Z shows divergent views, and trust in health authorities varies by country.
The study identifies three emotional mindsets—Optimists, Rationalists, Skeptics—and stresses transparency and human accountability as critical to building societal acceptance for innovations in AI, cell and gene therapy, new genomic techniques, and cultivated meat.
Bayer Canada (OTC: BAYRY) is funding the Bayer Entrance Award to cover full tuition for one student in the inaugural Simon Fraser University School of Medicine class, which begins with 48 students on the SFU Surrey campus in summer 2026; a permanent facility is planned by 2030.
The award targets applicants demonstrating leadership, service, and financial need to help address primary care shortages in British Columbia.